Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

New Study Tests Psilocybin in Adults with Autism

Stockhouse Editorial
1 Comment| May 10, 2022

{{labelSign}}  Favorites
{{errorMessage}}



(Video via COMPASS Pathways. Click to play.)

A mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health will be funding an investigator-initiated study that will use psilocybin to explore how psilocybin affects specific brain pathways in adults with autism.

In the first ever mechanistic study of psilocybin in adults with autism, COMPASS Pathways (NASDAQ: CMPS, Forum) will investigate whether there is a difference in the function of serotonin brain networks in adults with and without autism. The researchers will use a range of imaging techniques and behavioural tasks to examine how the serotonin system is modulated by COMP360 psilocybin. It is an investigator-initiated exploratory study that will take place at the Institute of Psychiatry, Psychology & Neuroscience (IoPPN) at King’s College London. The study will enrol 70 adult participants, including 40 people with autism and 30 without.

Speaking in a media release on this news, IoPPN Professor Grainne McAlonan said that the team’s long-term goal is to provide more and better tailored choices for autistic people and those with related conditions.

“Before embarking on clinical trials, we need to really understand brain mechanisms in autistic people.”

The company made further news on Tuesday upon the release of its financial results for Q1 2022, where it noted that R&D expenses were $15.4 million, compared with $6.9 million during the same period in 2021. Of this increase, $5.1 million was attributable to increased external development expenses as COMPASS progresses its COMP360 psilocybin therapy in TRD, and continues to explore additional indications and therapeutic approaches.

New to investing in Cannabis? Check out Stockhouse tips on How to Invest in Cannabis Stocks and some of our Top Cannabis Stocks.

For more of the latest info on Cannabis, check out the
Cannabis Trending News hub. Or, for lively sector discussion, visit Stockhouse’s new Cannabis Bullboards page.

Tags:

{{labelSign}}  Favorites
{{errorMessage}}

Comments

Pie in the sky
(121)
May 10, 2022

Leave a Comment

You must be logged in to be able to post a comment.

Get the latest news and updates from Stockhouse on social media

Follow STOCKHOUSE Today